Insulin aspart biosimilar (Gan & Lee)

门冬胰岛素生物类似药（甘李生物）

Report date: 2026/05/27 10:23:25

Base Information

Drug NameInsulin aspart biosimilar (Gan & Lee)
Drug Alias NameFast-acting aspartGL-ASP
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Global Approved IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
Original Approved Country/TerritoryMainland China
Original Approved Date2020/06/05
Country/TerritoryUnited StatesBangladeshGermany +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGan & Lee Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesGan & Lee Pharmaceuticals
Inactive CompaniesGan And Lee Pharmaceuticals, Usa
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeA10AB05A10AD05
Related LinksN/A